RECORDATI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.75 EUR | +1.10% |
|
+3.36% | +3.93% |
| Apr. 24 | Global markets live: Heineken, AT&T Hasbro, Visa, Boeing... |  |
| Apr. 24 | CVC Said Mulling Options for Majority Stake in Recordati | MT |
| Sales 2024 * | 2.3B 2.47B | Sales 2025 * | 2.44B 2.62B | Capitalization | 10.45B 11.24B |
|---|---|---|---|---|---|
| Net income 2024 * | 477M 513M | Net income 2025 * | 523M 563M | EV / Sales 2024 * | 5.12 x |
| Net Debt 2024 * | 1.31B 1.41B | Net Debt 2025 * | 1.08B 1.17B | EV / Sales 2025 * | 4.73 x |
| P/E ratio 2024 * |
22.7
x | P/E ratio 2025 * |
20.4
x | Employees | 4,455 |
| Yield 2024 * |
2.77% | Yield 2025 * |
3.05% | Free-Float | 46.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on Recordati
More press releases
More news
| 1 day | +1.10% | ||
| 1 week | +3.36% | ||
| Current month | +1.40% | ||
| 1 month | +1.87% | ||
| 3 months | +0.10% | ||
| 6 months | +15.47% | ||
| Current year | +3.93% |
1 week
49.14
51.15
1 month
48.3853.40
Current year
47.2953.40
1 year
40.6253.40
3 years
34.5257.90
5 years
28.2657.90
10 years
11.1257.90
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Koremans
CEO | Chief Executive Officer | 61 | 21-11-30 |
Luigi la Corte
DFI | Director of Finance/CFO | 54 | 19-10-31 |
Andrea Recordati
CHM | Chairman | 52 | 98-04-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cathrin Petty
BRD | Director/Board Member | 51 | 18-06-11 |
Giampiero Mazza
BRD | Director/Board Member | 55 | 18-06-11 |
Robert Koremans
CEO | Chief Executive Officer | 61 | 21-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.52% | 5 M€ | +12.55% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 50.75 | +1.10% | 257,183 |
| 24-05-02 | 50.2 | +0.30% | 282,441 |
| 24-04-30 | 50.05 | +1.27% | 185,142 |
| 24-04-29 | 49.42 | +0.65% | 134,018 |
| 24-04-26 | 49.1 | +0.61% | 273,233 |
Real-time Borsa Italiana, May 03, 2024 at 11:44 am EDT
More quotes
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.;
- medicines for rare diseases (32.1%).
Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
50.75
EUR
Average target price
52.14
EUR
Spread / Average Target
+2.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.93% | 11.25B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B |
- Stock Market
- Equities
- REC Stock
